Last reviewed · How we verify
half amount low molecular weight heparin
Low molecular weight heparin at reduced dosage inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa.
Low molecular weight heparin at reduced dosage inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa. Used for Thromboprophylaxis in surgical or medical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | half amount low molecular weight heparin |
|---|---|
| Also known as | Half amount enoxaparin |
| Sponsor | Beijing Anzhen Hospital |
| Drug class | Anticoagulant (low molecular weight heparin) |
| Target | Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller chains with a molecular weight of 3,000–10,000 Da. At half the standard dose, it provides anticoagulation through enhanced binding to antithrombin III, which then inactivates activated clotting factors, particularly factor Xa. This reduced-dose formulation may be used for thromboprophylaxis or treatment of thromboembolic conditions where standard dosing is not required.
Approved indications
- Thromboprophylaxis in surgical or medical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
- Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT) (PHASE3)
- The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: